Pasithea Therapeutics Corp. Company profile for Pasithea Therapeutics Corp. (KTTA) with a description, list of executives, contact details and other key facts. . Pasithea Therapeutics Corp. Pasithea Therapeutics Corp is a biotechnology . Pasithea Therapeutics has priced its IPO of 4.8M units, with each unit consisting of one share of common stock and one warrant to purchase one common share at $5.00/unit, for gross proceeds of ~$24M. Announces Pricing of Upsized $24.0 Million Initial Public Offering September 14, 2021 21:04 ET | Source: Pasithea Pasithea Operating Status Active. About Pasithea Therapeutics: S-1/A: IPO . (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. IPO Date: Sep 15, 2021: Industry: Biotechnology: Sector: Health Care: Employees: 3: Contact Details. Pasithea Therapeutics Corp. Financial Information: Market Cap: $55.78mil: Revenues: $0 mil (last 12 months) Net Income . 简介： 浙江阳云科技有限公司，成立于2019-08-21，注册资本为2000万人民币，法定代表人为王麒诚，经营状态为存续，工商注册号为330103000495681，注册地址为浙江省杭州市下城区永福桥路17号汉鼎国际大厦北楼1301室，经营范围包括服务：生物技术的技术开发、技术 . By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. Pasithea Therapeutics Corp. Financial Information: Market Cap: $55.78mil: Revenues: $0 mil (last 12 months) Net Income . ("IPO") in September 2021. In displaying the. About Pasithea Therapeutics Corp. 1111 LINCOLN ROAD SUITE 500, MIAMI BEACH, Florida, 33139, United States +1 702 514-4174 https://www.pasithea.com. From the start, our primary focus has been the creation of an . . miami beach, fla., march 30, 2022 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) ("pasithea" or the "company"), a novel biotechnology company focused on the research and discovery. 2021, Pasithea closed an initial public offering (IPO) that raised $24 million. Current price $2.69/share (as of market close 10-12-21)New NASDAQ listing only a month ago.Only 13M shares outstanding.Insiders own 52% of the outstanding shares.Growing market sector. "Pasithea was founded to improve treatment options for those affected by psychiatric and neurological disorders. Pasithea Therapeutics Corp. has completed an IPO in the amount of $24 million. The firm is developing drug treatments for depressive disorders. In displaying the financial viability of the space, Pasithea launched a new Biotech IPO on September 15th, and raised $24 million with their initial public offering. Complete Pasithea Therapeutics Corp. stock information by Barron's. View real-time KTTA stock price and news, along with industry-best analysis. Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022. . MIAMI (PRWEB) November 29, 2021 As the COVID-19 pandemic continues and the world works to adapt and recover to new ways of living, a new Biotech IPO is hoping to bring more interest into an important health sector: mental health. Pasithea (KTTA) is a New IPO and is Targeting Treatment-Resistant Depression and PTSD Using Ketamine Infusions. The UK branch of Pasithea's clinics is operating from a capital light partnership with Zen Healthcare, a leading group of practices with three locations in Marylebone, Holborn and Knightsbridge. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 PriceRange: $5 Discount. Current price $2.69/share (as of market close 10-12-21) New NASDAQ listing only a month ago. | May 22, 2022 Dr Tiago Reis Margues CEO of Pasithea Therapeutics Dr. Lawrence Steinman We use only highly qualified psychiatrist and anesthesiologists, who are assisted by expert registered nurses for their services throughout this innovative treatment. Last Funding Type Post-IPO Equity. September 15, 2021 2:59 pm. The warrants are exercisable at 125% of the offering . Latest Trade: $1.22 -0.01 (-0.8%) First Day Return: -28.8%. Companies; Documents; Forms; Alerts; Stock Ticker Lookup. IPO Investment Prospectus [Amended] 2021-09-10 17:15:24. Pasithea Therapeutics, a new and advanced company has partnered with IV Doc to provide in-home ketamine treatments to patients suffering with clinical depression and . By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. Pasithea Therapeutics ( NASDAQ: KTTA) intends to raise $17 million from the sale of its common stock in an IPO, according to an amended registration statement. Phone Number 702-514-4174. Legal Name Pasithea Therapeutics Corp. Stock Symbol NASDAQ:KTTA. Pasithea Therapeutics Corp is a biotech company aiming to solve one of the world's biggest clinical problems: brain disorders. The UK branch of Pasithea's clinics is operating from a capital light partnership with Zen Healthcare, a leading group of practices with three locations in Marylebone, Holborn and Knightsbridge. Founded Date 2020. We use only highly qualified psychiatrist and anesthesiologists, who are assisted by expert registered nurses for their services throughout this innovative treatment. EF Hutton, division of. Address: 1111 Lincoln Road Miami Beach, FL 33139 United States. 2021-08-26 18:26:44. The warrants KTTAW opened at $0.91. | May 22, 2022 Pasithea Clinics is committed to providing you with the best, most innovative and effective care possible. Pasithea Therapeutics, a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, filed . In displaying the . Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology company focused on treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. is . Security and exchange commission filings for Pasithea Therapeutics Corp.. Insider trades, quarterly, and annual reports. About Us World Class Management Team Pasithea is led by Professor Lawrence Steinman and the research is headed up by Dr. Tiago Reis Marques. By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. miami beach, fla., sept. 14, 2021 (globe newswire) -- pasithea therapeutics corp. ("pasithea" or the "company"), a biotechnology company focused on the research and discovery of new and effective. The future of mental health is here. FWP: Free Writing Prospectus. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range of $5 to $7. Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, raised $24 million by offering 4.8 million units at $5, the low end of the range of $5 to $7. . Pasithea Therapeutics Corp. has completed an IPO in the amount of $24 million. . Pasithea Therapeutics Corp. . The company issued 2,898,551 shares at $5.00-$7.00 per share. Return from IPO: -75.4%. "Pasithea was founded to improve treatment options for those affected by psychiatric and neurological disorders. ("IPO") in September 2021. The company offered 1.9 million more units than anticipated. In displaying the financial viability of the space, Pasithea launched a new Biotech IPO on September 15th, and raised $24 million with their initial public offering. Find the latest Pasithea Therapeutics Corp. (KTTA) stock quote, history, news and other vital information to help you with your stock trading and investing. . ("IPO") in September 2021. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range of $5 to $7. When did Pasithea Therapeutics IPO? Pasithea Therapeutics ( KTTA) has priced its IPO of 4.8M units, with each unit consisting of one share of common stock and one warrant to purchase one common share at $5.00/unit, for gross proceeds. By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. Pasithea Therapeutics has partnered with IV Doc to provide in-home ketamine treatments to those with clinical depression and anxiety. Search / Go. Summary. Pasithea Therapeutics has filed to raise $17.4 million in an IPO. Announces Closing of $24.0 Million Initial Public Offering. (Note: Pasithea Therapeutics upsized its IPO unit offering at pricing on Sept. 14, 2021, to 4.8 million units, up from 2.9 million units, and priced the units at $5, the low end of its $5-to-$7 range, to raise $24 million.) Founders Lawrence Steinman. . In displaying the. KTTA is still at a preclinical stage of development, the . . Phone: 2022, and an original unit price of $5.00 based on the IPO price, consisting of $4.99 for the share and $0.01 for the warrant. Industry: Health Care. ET on TipRanks.com With the Obesity Epidemic Bursting at the Seams, This Could Help Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology company focused on treatments for psychiatric and neurological disorders. September 15, 2021 2:59 pm Pasithea Therapeutics, a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, filed its. This was reported by Pasithea Therapeutics on November 29, 2021. "Pasithea was founded to . The company is developing psychiatric. August 6, 2021 Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. Pasithea Clinics is committed to providing you with the best, most innovative and effective care possible. (Note: Pasithea Therapeutics upsized its IPO unit offering at pricing on Sept. 14, 2021, to 4.8 million units, up from 2.9 million units, and priced the units at $5, the low end of its $5-to-$7 range, to raise $24 million.) The Group owns approximately 6% of the outstanding shares of Pasithea Therapeutics Corp. ("Pasithea" or the "Company") and to our knowledge represents the single largest shareholding body. August 6, 2021. In displaying the. EF Hutton Thinks Pasithea Therapeutics Corp's Stock is Going to Recover Dec. 15, 2021 at 4:11 a.m. We are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.Our biotech operations will focus on developing drugs that target the pathophysiology . Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health. Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022 . In displaying the financial viability of the space, Pasithea launched a new Biotech IPO on September 15th, and raised $24 million with their initial public offering. The warrants are exercisable at 125% of the offering price. Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022. . Pasithea Therapeutics trades on the NASDAQ under the ticker symbol "KTTA." By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 PriceRange: $5 Discount. What is Pasithea Therapeutics' stock symbol? The Company's Common Stock began trading on The Nasdaq Capital Market on September 15, 2021, under the symbol "KTTA." Pasithea Clinics has clinic partnerships both in the United States and in the United Kingdom to provide IV ketamine treatment. Pasithea Therapeutics recently raised $24 million at its initial public offering ("IPO"). MIAMI BEACH, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA . From the start, our primary focus has been the creation of an . we are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents … Today's IPO for Pasithea Therapeutics (NASDAQ: KTTA) opened for trading at $4.00 after pricing 4,800,000 units at $5.00 per unit.
Allulose Sugar Cookies, Memphis Brooks Museum Of Art Staff, Morgantown, Wv Traffic Accidents, Duke Football Attendance 2021, Frankenstein Quotes About Society, Frontier High School Class Of 2019, 341st Military Working Dog Training Squadron,